Sila Realty Trust Earnings Call Transcripts
Fiscal Year 2025
-
Strong 2025 results included modest NOI growth, improved tenant credit quality, and disciplined capital allocation. Portfolio optimization continued with acquisitions, redevelopments, and selective dispositions, while conservative leverage and ample liquidity position the company for further growth.
-
Q3 2025 saw strong growth in cash NOI and strategic acquisitions, with robust tenant coverage and a healthy balance sheet. The company remains focused on high-yield healthcare real estate, prudent capital allocation, and expects continued acquisition activity into 2026.
-
Q2 2025 saw strong operating results, 5% year-over-year cash NOI growth, and robust liquidity. Over $70M in acquisitions are under LOI, share repurchases continued, and the Stoughton asset is being demolished to reduce costs. Portfolio lease rate is now 99.2%.
-
Solid Q1 2025 results with stable occupancy, strong liquidity, and disciplined acquisitions. AFFO and NOI declined year-over-year due to non-recurring items and tenant bankruptcies, but leverage remains low and the portfolio is well-positioned for long-term growth.
Fiscal Year 2024
-
Delivered strong 2024 results with higher net income, robust leasing, and improved tenant credit metrics. Upsized credit facility, maintained low leverage, and targets 7.5%-15% growth in 2025, focusing on accretive acquisitions and disciplined capital allocation.
-
Q3 2024 saw lower year-over-year net income and AFFO, but sequential growth and strong liquidity. Portfolio remains diversified, with new acquisitions and a robust pipeline, while challenges from tenant bankruptcies are being managed.
-
Reported Q2 2024 net income of $4.6M and AFFO of $30.8M, with a 97.5% leased, diversified healthcare portfolio. Maintains strong liquidity and conservative leverage, targeting 10%-15% annual growth and actively managing vacancies from GenesisCare and Steward.